Regeneron
Market Access/ News/ News/ News/ Sales and Marketing
Dupixent claims new territory in eosinophilic oesophagitis
Phil Taylor
Dupixent, eosinophilic oesophagitis, Immunology and inflammation, Regeneron, regulatory approval, Sanofi
0 Comment
News/ News/ News/ Oncology/ R&D
Regeneron seeks CheckMate in immuno-oncology play
Phil Taylor
CheckMate Pharma, head and neck cancer, immuno-oncology, M&A, melanoma, Oncology, Regeneron, toll-like receptor agonist, vidutolimod
0 Comment
FDA says no to AZ’s Fasenra for nasal polyp indication
Phil Taylor
AstraZeneca, Dupixent, Fasenra, GlaxoSmithKline, nasal polyps, Nucala, Regeneron, regulatory, Sanofi
0 Comment
Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Phil Taylor
chronic spontaneous urticaria, Dupixent, ligelizumab, Novartis, Regeneron, Roche, Sanofi, Xolair
0 Comment
Oxurion reports stronger data for diabetic eye disease drug
Phil Taylor
Bayer, diabetic macular oedema, Eylea, ophthalmology, Oxurion, Regeneron
0 Comment
Pfizer sees no way forward for Ionis-partnered vupanorsen
Phil Taylor
antisense drugs, cardiovascular, Ionis Pharmaceuticals, Pfizer, Regeneron
0 Comment
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Phil Taylor
Bayer, DME, Eylea, ophthalmology, Regeneron, regulatory approval, Roche, Susvimo, Vabysmo, wet AMD
0 Comment
News/ News/ Sales and Marketing
FDA bans use of Lilly, Regeneron COVID drugs due to Omicron
Phil Taylor
antibody, coronavirus, COVID-19, Eli Lilly, Regeneron, Sales and Marketing
0 Comment